异动解读 | 轩竹生物-B上市首日大涨163.79%，创新药管线引发投资热潮

异动解读

Oct 15

轩竹生物-B（02575.HK）今日在港交所主板正式挂牌上市，盘中股价大涨163.79%，引发市场广泛关注。该股上市首日表现亮眼，充分反映了投资者对创新生物制药企业的热情。

轩竹生物-B此次IPO定价为每股11.60港元，共发行6733.35万股H股。公开发售部分获得4908.33倍超额认购，国际配售部分获得10.15倍认购，显示出投资者对公司前景的看好。上市首日开盘价为29.46港元，较发行价上涨153.97%，随后继续攀升。

轩竹生物是一家专注于创新药物研发的生物制药公司，其管线涵盖消化系统疾病、肿瘤和非酒精性脂肪肝炎（NASH）等领域。公司已有三款创新药物获得新药申请（NDA）批准，包括治疗消化系统疾病的质子泵抑制剂KBP-3571、用于乳腺癌治疗的CDK4/6抑制剂XZP-3287，以及针对非小细胞肺癌的ALK抑制剂XZP-3621。这些创新药物的商业化前景被市场看好，成为推动股价上涨的重要因素。

分析人士指出，轩竹生物-B的强劲表现不仅反映了公司自身的研发实力和商业化潜力，也体现了投资者对中国生物医药行业整体前景的信心。随着公司进入快速发展期，市场将继续关注其创新药物的临床进展和商业化情况。然而，投资者也应注意生物医药行业的高风险特性，合理评估公司的长期发展潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1131136011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131136011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131136011?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-15 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131136011","market":"nz","top_or_hot":-1,"title":"异动解读 | 轩竹生物-B上市首日大涨163.79%，创新药管线引发投资热潮","media":"异动解读","content":"<p>轩竹生物-B（02575.HK）今日在港交所主板正式挂牌上市，盘中股价大涨163.79%，引发市场广泛关注。该股上市首日表现亮眼，充分反映了投资者对创新生物制药企业的热情。</p>\n\n<p>轩竹生物-B此次IPO定价为每股11.60港元，共发行6733.35万股H股。公开发售部分获得4908.33倍超额认购，国际配售部分获得10.15倍认购，显示出投资者对公司前景的看好。上市首日开盘价为29.46港元，较发行价上涨153.97%，随后继续攀升。</p>\n\n<p>轩竹生物是一家专注于创新药物研发的生物制药公司，其管线涵盖消化系统疾病、肿瘤和非酒精性脂肪肝炎（NASH）等领域。公司已有三款创新药物获得新药申请（NDA）批准，包括治疗消化系统疾病的质子泵抑制剂KBP-3571、用于乳腺癌治疗的CDK4/6抑制剂XZP-3287，以及针对非小细胞肺癌的ALK抑制剂XZP-3621。这些创新药物的商业化前景被市场看好，成为推动股价上涨的重要因素。</p>\n\n<p>分析人士指出，轩竹生物-B的强劲表现不仅反映了公司自身的研发实力和商业化潜力，也体现了投资者对中国生物医药行业整体前景的信心。随着公司进入快速发展期，市场将继续关注其创新药物的临床进展和商业化情况。然而，投资者也应注意生物医药行业的高风险特性，合理评估公司的长期发展潜力。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 轩竹生物-B上市首日大涨163.79%，创新药管线引发投资热潮</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 轩竹生物-B上市首日大涨163.79%，创新药管线引发投资热潮\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-10-15 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>轩竹生物-B（02575.HK）今日在港交所主板正式挂牌上市，盘中股价大涨163.79%，引发市场广泛关注。该股上市首日表现亮眼，充分反映了投资者对创新生物制药企业的热情。</p>\n\n<p>轩竹生物-B此次IPO定价为每股11.60港元，共发行6733.35万股H股。公开发售部分获得4908.33倍超额认购，国际配售部分获得10.15倍认购，显示出投资者对公司前景的看好。上市首日开盘价为29.46港元，较发行价上涨153.97%，随后继续攀升。</p>\n\n<p>轩竹生物是一家专注于创新药物研发的生物制药公司，其管线涵盖消化系统疾病、肿瘤和非酒精性脂肪肝炎（NASH）等领域。公司已有三款创新药物获得新药申请（NDA）批准，包括治疗消化系统疾病的质子泵抑制剂KBP-3571、用于乳腺癌治疗的CDK4/6抑制剂XZP-3287，以及针对非小细胞肺癌的ALK抑制剂XZP-3621。这些创新药物的商业化前景被市场看好，成为推动股价上涨的重要因素。</p>\n\n<p>分析人士指出，轩竹生物-B的强劲表现不仅反映了公司自身的研发实力和商业化潜力，也体现了投资者对中国生物医药行业整体前景的信心。随着公司进入快速发展期，市场将继续关注其创新药物的临床进展和商业化情况。然而，投资者也应注意生物医药行业的高风险特性，合理评估公司的长期发展潜力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1131136011","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131136011","pubTimestamp":1760491949,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"轩竹生物-B今日在港交所主板正式挂牌上市，盘中股价大涨163.79%，引发市场广泛关注。该股上市首日表现亮眼，充分反映了投资者对创新生物制药企业的热情。轩竹生物-B此次IPO定价为每股11.60港元，共发行6733.35万股H股。上市首日开盘价为29.46港元，较发行价上涨153.97%，随后继续攀升。分析人士指出，轩竹生物-B的强劲表现不仅反映了公司自身的研发实力和商业化潜力，也体现了投资者对中国生物医药行业整体前景的信心。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"Interpretation of changes | Xuanzhu Bio-B soared 163.79% on the first day of listing, and the innovative drug pipeline triggered an investment boom","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"轩竹生物-B（02575.HK）今日在港交所主板正式挂牌上市，盘中股价大涨163.79%，引发市场广泛关注。该股上市首日表现亮眼，充分反映了投资者对创新生物制药企业的热情。\n轩竹生物-B此次IPO定价为每股11.60港元，共发行6733.35万股H股。公开发售部分获得4908.33倍超额认购，国际配售部分获得10.15倍认购，显示出投资者对公司前景的看好。上市首日开盘价为29.46港元，较发行价上涨153.97%，随后继续攀升。\n轩竹生物是一家专注于创新药物研发的生物制药公司，其管线涵盖消化系统疾病、肿瘤和非酒精性脂肪肝炎（NASH）等领域。公司已有三款创新药物获得新药申请（NDA）批准，包括治疗消化系统疾病的质子泵抑制剂KBP-3571、用于乳腺癌治疗的CDK4/6抑制剂XZP-3287，以及针对非小细胞肺癌的ALK抑制剂XZP-3621。这些创新药物的商业化前景被市场看好，成为推动股价上涨的重要因素。\n分析人士指出，轩竹生物-B的强劲表现不仅反映了公司自身的研发实力和商业化潜力，也体现了投资者对中国生物医药行业整体前景的信心。随着公司进入快速发展期，市场将继续关注其创新药物的临床进展和商业化情况。然而，投资者也应注意生物医药行业的高风险特性，合理评估公司的长期发展潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}